xolair 150 mg/1 ml rastvor za injekciju u napunjenoj šprici
novartis ba d.o.o. - omalizumab - rastvor za injekciju u napunjenoj šprici - 150 mg/1 ml - 1 ml rastvora za injekciju u napunjenoj šprici sadrži: 150 mg omalizumaba
signifor 0.3 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - пасиреотид - rastvor za injekciju - 0.3 mg/1 ml - 1 ml rastvora za injekciju sadrži: 0,3 mg pasireotida (u obliku pasireotid diaspartata)
signifor 0.6 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - пасиреотид - rastvor za injekciju - 0.6 mg/1 ml - 1 ml rastvora za injekciju sadrži: 0,6 mg pasireotida (u obliku pasireotid diaspartata)
signifor 0.9 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - пасиреотид - rastvor za injekciju - 0.9 mg/1 ml - 1 ml rastvora za injekciju sadrži: 0,9 mg pasireotida (u obliku pasireotid diaspartata)
durogesic 25 µg/1 hr transdermalni flaster
inpharm co. d.o.o. banja luka - fentanil - transdermalni flaster - 25 µg/1 hr - 1 transdermalni flaster sadrži: 4,2 mg/10,5 cm2 (25 mcg/h) fentanil
durogesic 50 µg/1 hr transdermalni flaster
inpharm co. d.o.o. banja luka - fentanil - transdermalni flaster - 50 µg/1 hr - 1 transdermalni flaster sadrži: 8,4 mg/21 cm2 (50 mcg/h) fentanil
durogesic 100 µg/1 hr transdermalni flaster
inpharm co. d.o.o. banja luka - fentanil - transdermalni flaster - 100 µg/1 hr - 1 transdermalni flaster sadrži: 16,8 mg/42 cm2 (100 mcg/h) fentanil
klavamox 875 mg/1 tableta+ 125 mg/1 tableta filmom obložena tableta
amsal pharmaceuticals d.o.o. - amoksicilin, klavulanska kiselina - filmom obložena tableta - 875 mg/1 tableta+ 125 mg/1 tableta - jedna filmom obložena tableta sadrži: 875 mg amoksicilina (u obliku amoksicilin trihidrata) 125 mg klavulanske kiseline (u obliku kalij klavulanata)
cosentyx 75 mg/0.5 ml rastvor za injekciju u napunjenoj šprici
novartis ba d.o.o. - sekukinumab - rastvor za injekciju u napunjenoj šprici - 75 mg/0.5 ml - 1 napunjena šprica od 0,5 ml rastvora za injekcije sadrži : 75 mg sekukinumaba
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.